Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the overall efficacy of aripiprazole
intramuscular (IM) depot as acute treatment in subjects with schizophrenia.
The secondary purpose is to evaluate the safety and tolerability of aripiprazole IM depot
administered every 4 weeks for 12 weeks to adult subjects with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.